Protocol Ledger

NCT03684278 · Phase II · RECRUITING

Randomised Treatment of Acute Pancreatitis With Infliximab: Double-blind, Placebo-controlled, Multi-centre Trial (RAPID-I)

Interventional Phase II clinical trial protocol NCT03684278 sponsored by University of Liverpool in Gastroenterology, Hepatology, and Renal, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-05-01 Enrollment: 240 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT03684278
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)240 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03684278
Protocol FieldVerified Registry Value
NCT IdentifierNCT03684278
Consolidated Lead SponsorUniversity of Liverpool
Therapeutic Condition CohortGastroenterology, Hepatology, and Renal
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment240 participants (ESTIMATED)
Registered Start Date2019-05-01
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT03684278
Hospital Research SiteLocationSite Profile
University Hospital of WalesCardiff, United KingdomOpen Hospital Dossier ->
University College London HospitalLondon, United KingdomOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Gastroenterology, Hepatology, and Renal Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI